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Copyright © 2009 AHC Nephronophthisis (NPHP) is the most frequent genetic cause of end-stage kidney disease
in children and young adults. Inv mice are a model for human nephronophthisis type 2
(NPHP2) and characterized by multiple renal cysts and situs inversus. Renal epithelial cells
in  inv cystic kidneys show increased cell proliferation. We studied the ERK pathway to
understand the mechanisms that induce cell proliferation and renal cyst progression in inv
kidneys. We studied the effects of ERK suppression by administering PD184352, an oral
mitogen-activated protein kinase kinase (MEK) inhibitor on renal cyst expansion, extra-
cellular signal-regulated protein kinase (ERK) activity, bromo-deoxyuridine (BrdU) incorpora-
tion and expression of cell-cycle regulators in invΔC kidneys. Phosphorylated ERK (p-ERK)
level increased along with renal cyst enlargement. Cell-cycle regulators showed a high level
of expression in invΔC kidneys. PD184352 successfully decreased p-ERK level and inhibited
renal cyst enlargement. The inhibitor also decreased expression of cell-cycle regulators and
BrdU incorporation in renal epithelial cells. The present results showed that ERK regulated
renal cell proliferation and cyst expansion in inv mutants.
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I. Introduction
Nephronophthisis (NPHP), the most frequent genetic
cause of end-stage kidney disease in children and young
adults, is characterized by a variable number of renal cysts
associated with cortical tubular atrophy and interstitial fibro-
sis [5]. Nine genes responsible for NPHP have been identi-
fied [5]. The infantile form of NPHP progresses to terminal
renal failure before the age of 5 years [4], and is found to be
caused by a mutation in the Invs/NPHP2 gene [10]. The
mouse homolog of the NPHP2 gene is inv that encodes 1062
amino acids with ankyrin repeats in N-terminus and two
nuclear localization signals and IQ domains in C-terminal
half [6]. Although the inv protein contains nuclear local-
ization signals, the protein is found to localize in the cilia
of renal epithelial cells [14, 15, 23]. The inv gene was first
discovered as the gene responsible for mouse inv mutant
[6, 25]. Human NPHP2 was then identified as mouse inv
homolog [10].
The inv mouse shows a reversal of left-right asymme-
try, jaundice and multiple renal cysts [25]. Kidneys of inv
mutant exhibit dilatation of all the segments of nephrons re-
sembling infantile NPHP2 [12]. Most inv/inv mutant mice
die before 7 days of age, probably because of cardiovascular
malformations caused by situs abnormalities. The invΔC
mouse was created by introduction of an inv gene that lacked
a C-terminus fused with GFP into an inv mouse [23]. The
lacking C-terminus region contains an important sequence
that regulates Inv localization in the cilia [15]. InvΔC mice
(inv/inv carrying two invΔC transgenic alleles) develop renal
cysts, but do not show any situs abnormality and jaundice,
and can survive beyond 6 weeks of age. Furthermore, renal
cysts grow slowly in this model, which makes invΔC mice
suitable for study of the mechanism of renal cyst progression
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Augmented cell proliferation is a common feature in
renal cystic diseases including human polycystic kidney
diseases (PKDs) and NPHPs as well as mouse mutants
with polycystic kidneys. A recent study has shown that
roscovitine, a cyclin-dependent kinase (CDK) inhibitor,
effectively inhibits renal cyst progression in jck and cpk
mice [2]. Thus, cell proliferation is a critical component
for renal cyst progression. Kidneys of inv as well as invΔC
mice also are shown to increase cell proliferation [19]. Al-
though the exact mechanisms that induce cell proliferation
are unknown in renal cystic diseases, the abnormality of
several intracellular signaling pathways has been reported
[1, 7, 8, 17, 18, 22]. In inv mutants, lack of inv protein is pro-
posed, but has not been shown to induce continuous activa-
tion of the canonical wnt pathway, which is assumed to
lead to cyst formation [18]. In other renal cystic mutants,
including bpk, pcy mice and Ham: SPRD rats, as well as
renal epithelial cells from human autosomal dominant poly-
cystic kidney disease (ADPKD) patients, activation of the
ERK pathway has been reported [7, 9, 22]. Omori et al.
have shown that suppression of ERK activity by administra-
tion of an oral MEK inhibitor, PD184352, inhibits renal cyst
enlargement in pcy mice [9]. However, Shibasaki et al.
have reported that activation of the ERK pathway did not
correlate with cell proliferation, although the pathway is
activated in renal cysts of conditionally Pkd1 knockout
mice [16]. Thus, the relationship between renal cell prolif-
eration and cyst development by the ERK activation is still
controversial.
In the present study, we studied if the ERK pathway
affects cell proliferation and renal cyst development in inv
mutants. We examined the ERK activation in invΔC cystic
kidneys, then treated invΔC mice with an oral MEK inhibi-
tor, PD184352 [9, 13, 20]. We examined the effect of ERK
inhibition on renal cyst expansion, and cell proliferation by
examination of bromo-deoxyuridine (BrdU) incorporation,
Rb phosphorylation and c-myc expression in invΔC kidneys.
II. Materials and Methods
Animals
Mice were maintained in the animal facility of Kyoto
Prefectural University of Medicine, Japan, as described pre-
viously [19, 23]. Studies with these mice were performed in
accordance with the Guide for the Care and Use of Labora-
tory Animals of National Institutes of Health and approved
by the Committee for Animal Research, Kyoto Prefectural
University of Medicine.
Histological and immunohistochemical analysis, and cell 
proliferation assay
For histological evaluation, mouse kidneys were fixed
in 4% paraformaldehyde (PFA) in PBS and embedded in
paraffin wax. Sections (4 μm thick) were stained with hema-
toxylin and eosin (H&E) according to standard protocols.
Immunohistochemical staining for p-ERK was performed
on paraffin-embedded sections. Anti-p-ERK antibody
(#4376, Cell Signaling Technology) was used. Cell prolifer-
ation was assayed by BrdU (Sigma) incorporation. BrdU
incorporation was detected with the specific antibody pro-
vided in the kit (Amersham), and was visualized using 3,3'-
diaminobenzidine tetrahydrochloride (DAB).
Administration of PD184352
Mice were weaned at 3 weeks of age. Male invΔC mice
(n=45) and normal littermate controls (+/+ or inv/+) (n=35)
were used for experiments. Sixteen invΔC and four control
mice were given PD184352 [13, 20] for 3 weeks, starting
from 3 weeks of age. PD184352 is an oral MEK inhibitor
that was given at 300 mg/kg/day and mixed in ground food.
At 6 weeks of age, animals were killed, and kidneys were
subjected to immunoblot and real-time RT-PCR analysis.
Biochemical analysis
Blood samples were obtained by cardiac puncture.
Blood urea nitrogen (BUN) and serum creatinine concentra-
tions were determined by Mitsubishi Kagaku Bio-Clinical
Laboratories.
Immunoblot analysis
Kidneys were homogenized with a Polytron in ice-cold
Tris lysis buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl,
100 mM NaF, 1 mM EDTA, 1 mM Na3VO4, and mammalian
cell protease inhibitor mixture (1:100 v/v, P8349; Sigma),
and sonicated with an Astrason ultrasonic processor for 10 s
on ice. Protein concentration of the homogenates was deter-
mined using Bradford reagent (B6916; Sigma). SDS-PAGE
and immunoblotting were carried out by standard proce-
dures. Samples (10 μg) were electrophoresed by 10 or 15%
SDS-PAGE and transferred onto polyvinylidene difluoride
membranes (Millipore). Membranes were blocked with 2%
non-fat dry milk (Difco), and were incubated with the fol-
lowing antibodies: anti-ERK (#9102), anti-p-ERK (#9101),
anti-phospho-retinoblastoma protein (p-Rb) (#9301) (Cell
Signaling Technology), and anti-actin (sc-1616; Santa Cruz
Biotechnology). Ras activation was assayed by the EZ-
Detect Ras activation kit (89855; Pierce Biotechnology).
The signals were visualized with the ECL-plus-detection
system (GE Healthcare Bio-sciences KK). Quantitation of
the chemiluminescent signals was performed with a digital
imaging system (VersaDoc; Bio-Rad).
Real-time RT-PCR analysis
Real-time RT-PCR was carried out on an Applied
Biosystems 7300 real-time PCR system. Glyceraldehyde
3-phosphate dehydrogenase (gapdh) was used as the control
gene for normalization. Each PCR amplification was per-
formed in a 25 μl reaction mixture containing 200 ng cDNA
and 2.5 ng/ml of each primer (Table 1), using the Power
SYBR® Green PCR Master Mix (Applied Biosystems). Five
control and experimental cystic kidneys were examined, and
data were collected from three independent experiments.ERK Activation in inv Mutant Mice 41
Statistical analysis
Data are expressed as mean±S.E. Comparison of the
data between the two groups was performed using an un-
paired t-test as appropriate. Multiple group comparison of
the data was performed using one-way ANOVA. p<0.05
was considered statistically significant. Statistical analysis
was performed using Excel 2004 (Microsoft) and Statcel2
plug-in software (OMS Publishing).
III. Results
Renal cyst development and ERK activation in invΔC mice
The body weight of invΔC mice was not significantly
different from that of controls at 1 and 3 weeks after birth,
but became significantly lower than that of controls at 6
weeks of age (p<0.05) (Table 2). The kidney weight of
invΔC mice was significantly greater than that of controls
(p<0.01) at 3 weeks of age, and three times larger than that
of controls at 6 week of age (p<0.01) (Table 2). Although no
significant difference was detected in either kidney or body
weight between control and invΔC mice at 1 week of age,
kidney weight to body weight ratio of invΔC mice was great-
er than that of control even at 1 week of age (Table 2). His-
tological section showed that small renal cysts were detected
as early as 1 week of age in some of the invΔC kidneys
(Fig. 1A). At 3 weeks of age, renal cysts were observed in all
examined invΔC mice, and at 6 weeks of age the whole
kidney was occupied with cysts in invΔC mice (Fig. 1A).
There was no difference in the total amount of ERK
protein between control and invΔC kidneys at all ages
(Fig. 1B). p-ERK level of invΔC kidneys was significantly
higher in 3- and 6-week-old mice compared with that in con-
trols (Fig. 1B). Intense p-ERK signals were detected by im-
munohistochemical staining of renal tissue at the epithelial
cells of renal cysts in 6-week-old invΔC kidneys (Fig. 1C).
PD184352 prevented renal cyst progression, and reduced 
ERK phosphorylation
PD184352 administration reduced kidney size in
invΔC mice (Fig. 2A and Table 3). The kidney weight of
PD184352-treated invΔC mice was significantly lower than
that of the untreated group (p<0.01). Kidney weight to body
weight ratio of PD treated invΔC group was significantly
lower than that of the untreated group (4.5±0.44% vs.
6.2±0.28%) (Table 3). The number of tubules >100 μm in
diameter decreased and the number of tubules <50 μm in
diameter increased in PD184352-treated compared to non-
treated invΔC kidneys (Fig. 2B). Creatinine and blood urea
nitrogen (BUN) concentration of the PD184352-treated
invΔC group were significantly lower than those of the
untreated group (p<0.05) (Table 3). Thus, PD184352 ame-
liorated both tubule structure and function of invΔC mice.
As shown in Figures 2C and D, PD184352 treatment
indeed decreased p-ERK level in invΔC kidneys when
compared to that in untreated invΔC kidneys. GTP-Ras/total
Ras ratio was unchanged between PD184352-treated and
untreated animals.
Effect of PD184352 treatment on cell proliferation, nuclear 
transcription factors regulated by ERK and cell cycle 
regulators in invΔC renal cysts
We next examined if PD184352 treatment inhibited
cell proliferation. InvΔC kidneys had higher BrdU in-
corporation than non-cystic control kidneys (Fig. 3A–D).
PD184352 treatment reduced this higher BrdU incorpora-
tion rate from 31.5% to 14.0%, p<0.01. To understand the
Table 1. Real-time RT-PCR primer list
Primer Sequences
gapdh F: 5'-CAATGTGTCCGTCGTGGATCT
R: 5'-TTGAAGTCGCAGGAGACAACC
c-fos F: 5'-GCAGCTATCTCCTGAAGAGGAA
R: 5'-TGGCAATCTCAGTCTGCAAC
c-myc F: 5'-TGAGCCCCTAGTGCTGCATGA
R: 5'-GGGGTTTGCCTCTTCTCCACAGA
VPV2R F: 5'-AGCGTGGGATCCAGAAGCTC
R: 5'-CAGCAAAGCAGGCTACGCAA
pkd1 F: 5'-GCCCAGAGCTCTCACAATCCT
R: 5'-GCGCTCATTAAGCACTGTGTAAGT
pkd2 F: 5'-GCCAAGCTGAAGAGACGAGA
R: 5'-AGCTGCATCATCCGATTCCC
Table 2. Body weight, kidney weight and kidney weight/body weight of control and invΔC mice
Examined mice are control mice (1w (n=15), 3w (n=10), and 6w (n=14)) and invΔC mice (1w (n=7), 3w (n=9) and 6w (n=10)).
* p<0.05 compared to the same age control.
** p<0.01 compared to the same age control.
Age (after birth) 1w 3w 6w
Body weight (g) Control 5.5±0.2 13.5±0.6 24.1±0.5
invΔC5 . 4 ±0.3 12.6±0.4 19.5±0.9*
Kidney weight (mg) Control 27.7±0.8 82.8±2.8 185.7±4.1
invΔC3 2 . 8 ±1.9 179.7±32.8** 560.4±33.1**
Kidney weight/Body weight (%) Control 1.0±0.01 1.2±0.01 1.6±0.04
invΔC1 . 2 2 ±0.04* 2.9±0.59* 5.9±0.41**Okumura et al. 42
mechanism of inhibition of cell proliferation by PD184352
treatment, we examined the expression of c-myc and c-fos,
nuclear transcription factors regulated by ERK, by real-time
RT-PCR analysis (Fig. 3E). Expression of these genes was
increased in invΔC kidneys and reduced by PD184352 treat-
ment. Rb phosphorylation is known to regulate G1-S transi-
tion in the cell cycle. As shown in Figures 3F and G, p-Rb
level in invΔC was increased compared to that in controls.
PD184352 administration reduced p-Rb level in invΔC
kidneys to the control level.
IV. Discussion
To search for a mechanism and a role for increased cell
proliferation observed in invΔC cystic kidneys, we exam-
ined the ERK pathway. We showed for the first time that the
ERK pathway was activated in invΔC cystic kidneys. p-
ERK-positive staining was observed in cyst lining cells,
which confirmed that cyst lining cells caused a high level of
p-ERK in invΔC cystic kidneys. The activation was low or
barely detectable in early-stage invΔC cystic kidneys, but
high in late-stage cystic kidneys, which indicated that ERK
activation correlated with renal cyst progression.
To see if ERK activation is a mere indicator or whether
it has any role in cell proliferation and cyst progression in
inv mutants, we suppressed ERK activity by PD184352.
PD184352 is known to inhibit exclusively ERK activation in
vivo [13]. Treatment with PD184352 reduced the high p-
ERK/total ERK ratio in invΔC kidneys to control levels.
PD184352 treatment inhibited enlargement of invΔC kid-
neys. Inhibition of kidney weight gain was not due to
suppression of kidney development, since PD184352 did
not affect development of non-cystic kidneys (data not
shown). The present study showed that kidney enlargement
and cell proliferation was dependent on ERK activation.
The present results also confirmed that ERK suppres-
sion inhibited activation of cell-cycle regulators such as Rb
phosphorylation and c-myc expression. p-Rb protein allows
E2F to become active and to push the cell through the cell
cycle progression [3]. PD184352 reduced p-Rb expression
that was increased in invΔC kidneys to the control level.
The c-myc gene is known to stimulate cell proliferation and
c-myc transgenic mice are known to produce renal cysts
[21]. PD184352 administration reduced the high level of
c-myc expression in invΔC cystic kidneys, which conversely
suggested that ERK activation was responsible for the high
Fig. 1. Renal cyst development and ERK activation in invΔC mice.
(A) H&E-stained kidneys of 1-, 3- and 6-week-old control and
invΔC mice. Bars=1 mm. (B) The upper panel shows immunoblot
analysis of p-ERK and total ERK proteins in 1-, 3- and 6-week-old
control and invΔC mice. The lower panel shows densitometric
quantitation of three independent immunoblots. Results are
expressed as a ratio of the density of p-ERK to total ERK. The
obtained values were further compared to the mean value from
1-week-old control mice. p-ERK level in invΔC mice started to
increase at 3-week-old compared to controls of the same age
(* p<0.05 compared to controls of the same age). (C) Immuno-
histochemical staining of p-ERK in 6-week-old invΔC kidneys
(right panel) and controls (left panel). Bars=100 μm.ERK Activation in inv Mutant Mice 43
level of c-myc expression. Our results suggest that ERK
activation promotes renal cyst enlargement by stimulating
cell proliferation. PD184352 treatment reduced increased
BrdU incorporation in cystic invΔC kidneys. Combined with
the recent report that roscovitine effectively inhibits renal
cyst progression [2], decreased cell proliferation by ERK
suppression is likely to suppress renal cyst enlargement.
PD184352 treatment reduced BrdU incorporation to
about half that in non-treated invΔC kidneys (14% versus
31.5%), but the incorporation was still high compared to
non-cystic controls (14% versus 2%). Oral dosing of
PD184352 in the present study could not achieve a complete
reduction in ERK activation. Therefore, the role of the ERK
pathway might be greater than that obtained in the present
study.
What stimulates ERK phosphorylation in invΔC kid-
neys? Ras is known to induce ERK activation [7, 11, 24].
We observed Ras activation (increased GTP-Ras) in cystic
Fig. 2. Effects of MEK inhibitor (PD184352) on renal cysts in invΔC mice. (A) Gross appearance of representative kidneys from control (left),
PD-treated invΔC (middle) and untreated invΔC (right) mice. Bars=1 cm. (B) Tubule diameter in control, untreated invΔC and PD-treated
invΔC kidneys. At least 500 tubules in each four kidneys were examined. PD administration decreased ratio of large tubules (>100 μm)
(# p<0.05 compared to untreated invΔC mice), and increased ratio of small tubules (<50 μm) (## p<0.01 compared to untreated invΔC mice).
(C) Immunoblot analysis of active and total components of Ras and ERK from control, untreated invΔC and PD-treated invΔC kidney tissue.
(D) Densitometric quantitation of three independent immunoblots. Results are expressed as a ratio of active to corresponding total ERK or Ras.
The obtained values were further compared to the mean value from controls. p-ERK, but not Ras-GTP was reduced in PD-treated invΔC com-
pared to untreated invΔC kidneys. ** p<0.01 compared to controls; * p<0.05 compared to controls; # p<0.05 compared to untreated invΔC mice.
Table 3. Effect of PD184352 treatment on body and kidney weight and renal function of invΔC mice
6-week-old control (n=29), invΔC (n=29), and invΔC+PD (invΔC treated with PD184352) (n=16) were examined.
** p<0.01 compared to control.
## p<0.01 compared to invΔC.
Control (n=29) invΔC (n=29) invΔC+PD (n=16)
Body weight (g) 25.0±0.33 19.5±0.52** 18.5±0.84
Kidney weight (mg) 202.5±4.7 595.0±19.9** 396.4±20.0 ##
Kidney weight/Body weight (%) 1.62±0.03 6.25±0.28** 4.55±0.44 ##
Creatinin (mg/dL) 0.097±0.010 0.49±0.087** 0.25±0.051 ##
BUN (mg/dL) 27.5±1.95 115.1±19.2** 58.3±0.79 ##Okumura et al. 44
kidneys, suggesting that Ras activation induced a high level
of ERK phosphorylation. It remains to be seen how mutation
or loss of inv protein results in Ras activation.
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